Specificity and selectivity profile of EP217609: a new neutralizable dual-action anticoagulant that targets thrombin and factor Xa

Steven T. Olson¹, Richard Swanson¹ and Maurice Petitou²

¹Center for Molecular Biology of Oral Diseases, University of Illinois at Chicago, Chicago, IL, USA and ²Endotis Pharma, Loos, France

Short title: Specificity and selectivity profile of EP217609

Scientific category: Thrombosis and Hemostasis

Corresponding author: Steven T. Olson, Center for Molecular Biology of Oral Diseases, University of Illinois at Chicago, 801 S. Paulina St., Rm 530C, Chicago, IL 60612; email: stolson@uic.edu Telephone: 312-996-1043; FAX: 312-413-1604
**Abstract:** EP217609 is a new dual-action parenteral anticoagulant that combines an indirect factor Xa inhibitor (fondaparinux analogue) and a direct thrombin inhibitor (α-NAPAP analogue) in a single molecule together with a biotin tag to allow avidin neutralization. EP217609 exhibits an unprecedented pharmacologic profile in showing high bioavailability, long plasma half-life and potent antithrombotic activity in animals without the complications of thrombin rebound. Here we report the exceptional specificity and selectivity profile of EP217609. EP217609 inhibited thrombin with rapid kinetics ($k_{on} >10^7 \text{ M}^{-1}\text{s}^{-1}$), a high affinity ($K_I$ 30-40 pM) and >1000-fold selectivity over other coagulation and fibrinolytic protease targets, comparing favorably with the best direct thrombin inhibitors known. EP217609 bound antithrombin with high affinity ($K_D$ 30 nM) and activated the serpin to rapidly ($k_{ass} \sim 10^6 \text{ M}^{-1}\text{s}^{-1}$) and selectively (>20-fold) inhibit factor Xa. The dual inhibitor moieties of EP217609 acted largely independently with only modest linkage effects of ligand occupancy of one inhibitor moiety on the potency of the other (~5-fold). In contrast, avidin binding effectively neutralized the potency of both inhibitor moieties (20-100-fold). These findings demonstrate the superior anticoagulant efficacy and rapid avidin neutralizability of EP217609 compared to anticoagulants that target thrombin or factor Xa alone.
Heparin has been the reference anticoagulant drug of choice for the prevention and
treatment of venous thrombosis for the past 70 years\(^1\). The anticoagulant activity of this natural
glycosaminoglycan derives from a specific pentasaccharide sequence that binds and activates the
plasma serpin inhibitor of blood coagulation proteases, antithrombin\(^2,3\). However, numerous off-
target interactions of heparin with other plasma proteins and cells compromise the effectiveness
and safety of this anticoagulant. Such interactions result in variable dosage requirements and
consequent risks of bleeding, the danger of eliciting the immune syndrome, heparin-induced
thrombocytopenia (HIT) and problems with thrombin rebound following anticoagulant
therapy\(^1,4-7\). The heparin pentasaccharide mimetics, fondaparinux and idraparinux, were
developed to eliminate such off-target interactions and have been shown to be specific
antithrombin-mediated inhibitors of factor Xa with predictable pharmacokinetic profiles and no
risk of HIT\(^8-11\). However, problems with thrombin-rebound remain with these mimetics which
appear to result from the inability to inhibit clot-bound thrombin\(^12\).

The predictable pharmacokinetics of fondaparinux was the impetus for developing a dual
factor Xa and thrombin inhibitor that combines a fondaparinux-like antithrombin-mediated
inhibitor of factor Xa with an \(\alpha\)-NAPAP-like direct thrombin inhibitor\(^13-16\). The first compound
of this generation, EP42675 (Fig. 1), inhibits free and clot-bound thrombin in a manner like that
of the related direct reversible thrombin inhibitor, and retains the anti-factor Xa activity,
complete bioavailability, long half-life and predictable pharmacokinetic properties of
fondaparinux. Moreover, it shows a strong antithrombotic activity in both arterial and venous
thrombosis models and no evidence of rethrombosis in an experimental thrombolysis model\(^17\).
Addition of a biotin tag to the structure of EP42675 yielded EP217609 (Fig. 1) that retained the
anti-IIa and anti-factor Xa activities and pharmacokinetics of EP42675 and could be rapidly
neutralized by avidin injection\textsuperscript{15}. In man, administration of avidin triggered a rapid and irreversible neutralization of EP217609 without rebound effect\textsuperscript{18}.

EP217609 is currently under investigation in a phase II clinical trial as a reversible anticoagulant in cardiopulmonary bypass (CBP) surgery. Surprisingly, the current standard of care for anticoagulation in CPB remains heparin and its neutralizing agent protamine, as safer or more efficacious anticoagulants have yet to be found\textsuperscript{19}. Low molecular weight heparin or the heparin-like danaparoid have been used in CPB but they produce inadequate thrombin inhibition and are not neutralized by protamine\textsuperscript{20,21}. The direct thrombin inhibitors bivalirudin and argatroban, have also been tested in patients but none of these agents represents a real alternative to the heparin-protamine couple\textsuperscript{22,23}. A new approach based on the use of a reversible selective factor IXa inhibitor is promising but has not been tested in man\textsuperscript{24}.

While EP217609 shows a promising pharmacologic profile, quantitative biochemical studies of the potency and selectivity of the dual inhibitor for its targets have not been done to provide a biochemical foundation for understanding its exceptional pharmacologic efficacy. Here we demonstrate that EP217609 is among the highest affinity (K\textsubscript{i} 30-40 pM) and selective (>1000-fold) direct thrombin inhibitors known and is a rapid (k\textsubscript{ass}~10\textsuperscript{6} M\textsuperscript{-1}s\textsuperscript{-1}) and selective (>20-fold) antithrombin-mediated inhibitor of factor Xa. Avidin binding directly neutralizes the dual inhibitor activities in addition to the indirect neutralization that results from accelerated clearance of the drug. Our findings support the promise of EP217609 as a next generation anticoagulant capable of reversible inhibition of both existing and newly generated thrombin. Current phase 2 clinical trials evaluating EP217609 anticoagulant efficacy in CPB will provide an important test of this promise.
Materials and Methods

Materials- Proteases of human origin were from Enzyme Research Laboratories and their concentrations determined by active-site titrations, as in prior studies\textsuperscript{25}. Human antithrombin was purified from blood plasma as described\textsuperscript{26}. Concentrations of the protein were determined from the absorbance at 280 nm using an extinction coefficient of 37,700 M\textsuperscript{-1}cm\textsuperscript{-1}.\textsuperscript{27} The recombinant extracellular domain of human tissue factor was a gift of the late Dr. Yale Nemerson. Egg white avidin was provided by Endotis Pharma. The concentration of avidin solutions was determined by HPLC comparing the area under the curve with that of a standard of known concentration. All proteins were judged pure by SDS-PAGE analysis\textsuperscript{28}. Synthetic p-nitroanilide chromogenic and 7-amido-4-methylcoumarin (AMC) fluorogenic protease substrates were purchased from Chromogenix, American Diagnostica, Centerchem or Sigma. Substrate concentrations were determined by absorbance using published extinction coefficients\textsuperscript{25}. The heparin pentasaccharide mimetics, fondaparinux and idraparinux\textsuperscript{8,9}, were provided by Sanofi-Aventis and their concentration determined by weight from the molecular weight. Endotis Pharma (EP) compounds were provided as aqueous solutions whose molar concentrations were determined by NMR spectroscopy using an internal standard.

Experimental conditions- All experiments except where otherwise noted were performed at 25°C in an I 0.15 buffer consisting of 100 mM Hepes, 93.5 mM NaCl, 5 mM CaCl\textsubscript{2}, 0.1% PEG 8000, pH 7.4.

Binding of EP compounds to antithrombin and thrombin- Stoichiometries and dissociation constants for the binding of EP compounds to antithrombin were measured by fluorescence titrations as in past studies\textsuperscript{26}. Stepwise additions of compounds to antithrombin were made followed by monitoring the increases in protein fluorescence that signal binding of the heparin
pentasaccharide mimetic group using $\lambda_{ex}$ 280 nm and $\lambda_{em}$ 340 nm. Titrations to determine binding stoichiometry were done in low ionic strength buffer consisting of 20 mM sodium phosphate, 0.1 mM EDTA, 0.1% PEG 8000, pH 7.4 whereas titrations to assess binding affinity were done in the I 0.15 Hepes buffer used for all other experiments. Fluorescence changes were fit by the quadratic equilibrium binding equation.\textsuperscript{26} For stoichiometric titrations, $K_D$ was fixed based on the ionic strength dependence of $K_D$ measured for fondaparinux\textsuperscript{10}, and the maximal fluorescence change and the stoichiometric factor were fit as adjustable parameters. The fitted stoichiometric factor was assumed in titrations to determine binding affinity, in which case $K_D$ and the maximal fluorescence change were the fitted parameters.

Binding of the EP compounds to thrombin was measured by fluorescence titrations in the presence of the probe, p-aminobenzamidine\textsuperscript{26}, by following the decrease in fluorescence at 370 nm ($\lambda_{ex}$ 330 nm) due to the displacement of bound p-aminobenzamidine from the thrombin active-site that accompanies compound binding. Fluorescence changes were fit by the quadratic equilibrium binding equation. The $K_D$ for the thrombin-EP compound interaction in these fits was fixed at the measured $K_I$ value\textsuperscript{26}. The maximal fluorescence change and stoichiometric factor were the fitted parameters.

Measurements of $K_I$ values for protease inhibition by the EP compounds- EP compounds were incubated with protease for several minutes followed by the addition of chromogenic or fluorogenic substrates to yield final concentrations of $10^{-10}$-$10^{-4}$ M EP compound, 0.1-5 nM protease and 50-100 $\mu$M substrate. The initial rate of substrate hydrolysis was then monitored continuously from the linear rate of absorbance change at 405 nm or fluorescence change at $\lambda_{ex}$ 380 nm, $\lambda_{em}$ 440 nm. For experiments with factor IXa, hirudin was included at 30 nM in reaction mixtures to inhibit traces of thrombin (estimated at 0.6% of factor IXa) due to the poor reactivity
of factor IXa with the synthetic substrate under the experimental assay conditions. The
dissociation constant for inhibitor binding, $K_I$, was evaluated for all proteases except thrombin
by fitting the decrease in the observed initial velocity of substrate hydrolysis, $v_{obs}$, as a function
of EP inhibitor concentration, $[I]_o$, by the hyperbolic equation,

$$v_{obs} = v_o \times [I]_o / (K_{I^*} + [I]_o)$$

where $v_o$ is the initial velocity of substrate hydrolysis in the absence of inhibitor and $K_{I^*}$ is the
apparent dissociation constant for inhibitor binding. $K_{I^*}$ is related to $K_I$ by a factor that
accounts for the competitive effect of substrate binding:

$$K_{I^*} = K_I \times (1 + [S]_o/K_M)$$

where $[S]_o$ is the fixed substrate concentration employed and $K_M$ is the Michaelis constant for the
protease-substrate interaction. Because of the tight binding of the EP compounds to thrombin, the
decrease in observed initial velocities of substrate hydrolysis with increasing EP compound
concentration was fit using the quadratic equation:

$$v_{obs} = v_o \times (n \times [E]_o \times [I]_o \times K_{I^*} + (([I]_o \times K_{I^*} - n \times [E]_o)^2 + 4 \times K_{I^*} \times n \times [E]_o)^{1/2})/(2 \times n \times [E]_o)$$

where $[E]_o$ is the total protease concentration, $n$ is a stoichiometric factor and all other
parameters are as indicated in the hyperbolic equation above. The fitted parameters were $v_o$, $n$, and $K_{I^*}$. It should be noted that under conditions where inhibitor dissociation from the protease
is slow relative to the time over which substrate hydrolysis is measured, the substrate will only
interact with the free protease and not compete with the inhibitor-bound protease and therefore
$K_{I^*}$ will be equal to $K_I$.

**Kinetics of protease reactions with antithrombin-EP compound complexes** - Kinetic studies of the
reactions of antithrombin-EP compound complexes or antithrombin-idraparinux complex with
proteases were performed similar to previous studies. Idraparinux was chosen as a reference
because of its high-affinity for antithrombin and because it activates antithrombin identical to fondaparinux.\textsuperscript{25} EP compound or idraparinux concentrations were in 1.5-fold molar excess over the antithrombin concentration except for reactions of proteases that bound the $\alpha$-NAPAP-like unit of the EP compounds with submicromolar $K_I$ values in which case the EP compound was equimolar with or lower than the antithrombin concentration to minimize competitive inhibition by the free EP compound. In all cases, the protease concentration was at least 10-fold lower than the concentration of antithrombin-EP compound complex to ensure pseudo-first order reaction conditions. Reactions were initiated by adding protease to antithrombin and EP compound or idraparinux followed by quenching after different time intervals with chromogenic or fluorogenic substrate solution\textsuperscript{25}. Factor Xa reactions were performed with a fixed antithrombin concentration and varying EP compound or idraparinux concentrations for a fixed time of 300 s and then quenched with substrate. Substrate quench solutions for factor IXa reactions contained ethylene glycol to enhance the reactivity of the enzyme with the substrate and preclude any interference from traces of thrombin\textsuperscript{30}. The residual enzyme activity was measured by monitoring the initial linear increase in absorbance or fluorescence for several minutes. Progress curves of the loss of enzyme activity with time were fit by a single exponential decay function to obtain the observed pseudo-first order inhibition rate constant ($k_{\text{obs}}$)\textsuperscript{25}. Second order rate constants ($k_{\text{ass}}$) were calculated by dividing $k_{\text{obs}}$ by the concentration of antithrombin-EP compound complex calculated from measured $K_D$ values for the interactions. The contribution of the free antithrombin reaction with protease was negligible relative to the faster reaction of the antithrombin-EP compound complex. At least two inhibitor-compound complex concentrations were analyzed and calculated second order rate constants were averaged. Errors reported represent the range of observed values for 2-5 independent experiments. For factor Xa reactions
the loss of enzyme activity as a function of EP compound concentration was fit by a single exponential and the second order association rate constant calculated by dividing the fitted exponential rate constant by the fixed reaction time and then correcting for the fraction of EP compound complexed with antithrombin based on the measured $K_D^{31}$.  

**Linkage effects** - The effect of antithrombin binding to the EP compound on the $K_I$ for thrombin binding was analyzed according to the linkage scheme and equation:

\[
K_{L,app} = \frac{(K_{EP,T} \times K_{EP-T,AT} + K_{EP-AT,T} \times [AT]_0)}{(K_{EP-T,AT} + [AT]_0)}
\]

where $K_{L,app}$ is the apparent $K_I$ measured in the absence or presence of antithrombin, $[AT]_0$ is the total antithrombin concentration, and $K_{EP,T}$, $K_{EP-T,AT}$, and $K_{EP-AT,T}$ are dissociation constants for thrombin binding to free EP, for antithrombin binding to the binary EP-thrombin complex, and for thrombin binding to the binary EP-antithrombin complex, respectively. $K_{EP-T,AT}$ was determined by comparing the kinetics of factor Xa inhibition by antithrombin complexes with free EP versus EP-thrombin binary complex based on the equation:

\[
K_{EP-T,AT} = \frac{k_{obs,-T}}{k_{obs,+T}} \times (K_{EP,AT} + [AT]_0) - [AT]_0
\]

where $k_{obs,-T}/k_{obs,+T}$ is the ratio of observed pseudo-first order rate constants for reactions of antithrombin complexes with free EP and EP-thrombin binary complex and $K_{EP,AT}$ is the dissociation constant for antithrombin binding to free EP. The measured values of $K_{L,app}$, $K_{EP,T}$, and $K_{EP-T,AT}$, were then used to calculate $K_{EP-AT,T}$ from the linkage equation.
Results

**EP compounds bind tightly to antithrombin and thrombin** - The ability of the EP compounds to bind both antithrombin and thrombin with high affinity was initially assessed by equilibrium binding titrations. Titrations of antithrombin with EP42675 and its biotin conjugate, EP217609 (Fig. 1), were monitored by changes in the tryptophan fluorescence of antithrombin that report binding of the fondaparinux-like moiety of the compounds\(^\text{10}\). At low ionic strength, the EP compounds produced identical linear increases in fluorescence up to an endpoint corresponding to a ~40% fluorescence enhancement after ~1 mole of compound/mole antithrombin had been added (Fig. 2A), indicating stoichiometric binding of the compounds to the serpin. Titrations at physiologic ionic strength resulted in more gradual hyperbolic increases in fluorescence with increasing additions of the two compounds that indistinguishably approached saturable endpoints equivalent to those observed at low ionic strength. Fitting of the latter titrations by the equilibrium binding equation indicated identical K\(_D\)s of 30-32 nM, representing binding affinities ~2-fold stronger than fondaparinux (K\(_D\) 60 nM), but ~60-fold weaker than the mimetic, idraparinux (K\(_D\) 0.4 nM), which has an additional two sulfates\(^9,32\) (Table 1).

Fig. 2B shows equilibrium binding titrations of thrombin with the EP compounds monitored from decreases in fluorescence of the probe, p-aminobenzamidine, that report the competitive displacement of the probe from the enzyme active-site as the compounds bind\(^33\). Titrations of thrombin with both EP compounds showed equivalent linear decreases in probe fluorescence to an endpoint fluorescence corresponding to that of the free probe after ~1 mole of compound/mole thrombin had been added. This indicated tight stoichiometric binding of the EP compounds to the active-site of thrombin.
The endpoints observed in the stoichiometric titrations of thrombin and antithrombin with the EP compounds were experimentally indistinguishable and showed equivalent minor deviations (~30%) from theoretical 1:1 endpoints, presumably due to errors in compound concentrations determined by NMR. For consistency, corrected compound concentrations, obtained by equating concentrations observed at the titration endpoints with the antithrombin or thrombin concentrations employed, were used in measuring $K_I$ values for direct inhibition of proteases and in determining second order association rate constants for antithrombin-dependent inhibition of proteases.

*EP compounds are highly selective active-site-directed inhibitors of thrombin*—The relative inhibitory potency of the $\alpha$-NAPAP-like moiety of the EP compounds against seven procoagulant proteases and three anticoagulant proteases was evaluated by equilibrium binding titrations under conditions approximating physiologic (I 0.15, pH 7.4, 5 mM Ca$^{2+}$), although at a temperature of 25°C. Titrations were monitored from the inhibitory effect of the compounds on the initial velocity of hydrolysis of specific chromogenic or fluorogenic substrates by the proteases. (Fig. 3).

Inhibition of thrombin enzymatic activity by the EP compounds was essentially stoichiometric when ~1 nM thrombin was titrated, indicating tight binding (Fig. 4A). Excellent fits of the titrations by the equation for a tight binding competitive inhibitor were observed. Indistinguishable apparent $K_I$ values were found when thrombin titrations were performed in the presence of substrates with a low $K_M$ (S2238) or high $K_M$ (S2366) (data not shown), indicating that the reporter substrates measure equivalent free thrombin concentrations in the titrations due to the slow dissociation of bound compound from thrombin during the time of measurement. The apparent $K_I$ thus represents the true $K_I$ and requires no correction for substrate binding$^{29}$. 
The measured $K_I$ for binding of the nonbiotinylated EP42675 to thrombin was 61±20 pM (Table 2). The biotin label of EP217609 increased the affinity to 43±16 pM, although the significance of these differences was marginal due to the large errors in $K_I$ at the protease concentration employed (~20 x $K_I$). Titrations performed at a 10-fold lower thrombin concentration confirmed the $K_I$ values measured at higher thrombin concentration and the modestly higher affinity of thrombin for the biotin-labeled than the unlabeled compound (Fig. 4A).

Continuous measurements of the kinetics of EP compound inhibition of thrombin were performed by adding thrombin to mixtures of the low $K_M$ fluorogenic substrate and EP compound and following the exponential decrease in the rate of substrate hydrolysis to a final equilibrium inhibited value under pseudo-first order conditions. From measurements of $k_{obs}$ as a function of inhibitor concentration, identical values for $k_{on}$ of $3.6±0.2 \times 10^7$ M$^{-1}$s$^{-1}$ and similar values for $k_{off}$ of $1.5±4 \times 10^{-4}$ s$^{-1}$ were determined for EP42675 and EP217609 from the observed linear relationship between $k_{obs}$ and EP concentration (Fig. 4B). These kinetic constants were consistent with the measured $K_I$s and confirmed an extremely slow rate of inhibitor dissociation from thrombin ($t_{1/2} > 20$ minutes).

The substrate hydrolysis activity of five other proteases was inhibited by the EP compounds over the range of inhibitor concentrations examined (Fig. 3). Because inhibitor concentrations greatly exceeded protease concentrations in these titrations, inhibition of each of the proteases was well fit by the equation for simple hyperbolic competitive inhibition. Corrections of apparent inhibition constants for substrate binding were applied in each case. Two proteases, factor XIa and activated protein C (aPC), bound the EP compounds with moderately high affinities (Table 2). aPC bound the parent EP42675 with a $K_I$ of 40±3 nM, an affinity still
1000-fold weaker than that for thrombin. The biotin label modestly weakened the affinity to a $K_I$ of 50±6 nM. Factor Xla bound EP42675 with a $K_I$ of 290±20 nM, an affinity ~5000-fold weaker than that for thrombin. The binding was significantly improved with the biotin-labeled EP217609 ($K_I$ 170±10 nM). EP42675 bound the three proteases, plasmin, kallikrein and factor Xa with $K_I$ values of 5.2±0.3 μM, 22±1 μM and 82±4 μM, respectively, that reflected affinities >100,000-fold weaker than that for thrombin. The biotin-labeled EP217609 modestly enhanced binding to these proteases by 2-3-fold (Table 2). No evidence for any biphasic slow inhibition kinetics reflecting a possible two-step inhibition mechanism was observed for any of the EP compound-protease interactions. The compounds thus appear to inhibit all proteases through a simple one-step reversible equilibrium.

No significant inhibition by the EP compounds was observed for several of the proteases up to $10^{-5}$ M compound, including factor IXa, factor VIIa-tissue factor complex, factor XIIa and tPA (Fig. 3). $K_I$ values for EP compound binding to these proteases were thus estimated to greatly exceed 10 μM (Table 2).

*Antithrombin-EP compound complexes selectively inhibit factor Xa*—Progress curves for the inhibition of the enzymatic activity of the procoagulant and anticoagulant proteases by antithrombin complexes with EP compounds and with the reference compound, idraparinux, were compared under the same conditions as $K_I$ determinations and under pseudo-first order reaction conditions. Observed pseudo-first order rate constants ($k_{obs}$) for the inhibition reactions were proportional to the antithrombin-EP compound complex concentration in all cases, providing the second-order rate constants ($k_{ass}$) in Table 3. $k_{ass}$ values were experimentally indistinguishable for reactions of any protease with antithrombin complexed with either
EP42675 or EP217609, indicating no effect of the biotin tag. Comparison of k_{ass} values for all protease reactions showed that antithrombin-EP complexes preferentially inhibited factor Xa with a pharmacologically significant rate constant of $\sim 10^6 \text{ M}^{-1}\text{s}^{-1}$ and with >20-fold selectivity over other proteases. This protease reaction profile resembled that of the antithrombin-idraparinux complex except for proteases that were directly inhibited by the $\alpha$-NAPAP-like part of the EP compound. The proteases that bound the $\alpha$-NAPAP-like moiety with the highest affinity, thrombin, aPC and factor XIa, showed either no detectable antithrombin-mediated inhibition by the EP compounds or a significantly reduced rate of inhibition relative to reactions with the antithrombin-idraparinux complex. This was fully accounted for by competitive inhibition of the antithrombin-mediated reaction by the $\alpha$-NAPAP-like part of the EP compounds. Such competitive effects thus amplified the selectivity of the antithrombin-EP complex for inhibiting factor Xa relative to these proteases.

**Stereoisomeric configuration of EP217609 is unimportant for direct and antithrombin-mediated inhibition of proteases**- Because the biotin tag of EP217609 is attached at a chiral carbon, the compound consists of a mixture of two diastereoisomers, EP217609-1 and EP307138-1 (Fig. 1). K_{I} values and second order rate constants for direct and antithrombin-mediated inhibition of proteases by the separate stereoisomers were therefore measured. The configuration of the biotin tag had minimal effect on the K_D for binding of the stereoisomers to antithrombin (Table 1) or on K_{I} values measured for direct inhibition of thrombin, aPC, plasmin, kallikrein, and factor Xa by the stereoisomers (Table 2). Only the direct inhibition of factor XIa was significantly affected by the biotin orientation, EP307138-1 binding with ~4-fold higher affinity than EP217609-1 with the diastereomer mixture of EP217609 binding with intermediate affinity. Second order rate constants for antithrombin-dependent inhibition of proteases by the EP stereoisomers similarly
showed little or no significant differences between the stereoisomers for any of the proteases except for factor Xla (Table 3). The latter were accounted for by differential competitive inhibition by the direct inhibitor parts of the compounds.

**Linkage effects on inhibitor potency**- Since at plasma concentrations of antithrombin (2-3 μM), EP217609 is expected to be fully complexed with the serpin given the measured K_D for this interaction, it was important to determine how antithrombin binding to the fondaparinux-like unit of the compound affects the binding of the α-NAPAP-like unit to proteases. This was assessed for the three proteases that bound the inhibitor with the highest affinity, namely thrombin, aPC and factor Xla. Comparison of titrations of these proteases with the EP compounds in the absence and presence of antithrombin levels that caused minimal antithrombin-mediated inhibition over the time of measurement, showed that the serpin reduced the affinity of the EP compounds for the proteases from ~2-fold for thrombin at 0.1 μM antithrombin to 5-7-fold for aPC and factor Xla at 0.5-1 μM serpin (Fig. 5A).

To validate that the observed linkage of antithrombin binding and protease binding to the EP compounds was reciprocal, we evaluated the effect of thrombin at levels equimolar with EP42675 or EP217609 on the inhibition of factor Xa by the antithrombin-EP binary complex (Fig. 5B). A modest, but highly reproducible ~30% decrease in the exponential rate constant for factor Xa inhibition was observed for both EP compounds in the presence of equimolar thrombin. Assuming that this decrease reflects a reduced affinity of the EP compound for antithrombin, we calculated an affinity loss of ~5-fold (K_D 150 nM) (see Methods). This loss in antithrombin affinity suggested that the ~2-fold decrease in EP affinity for thrombin observed at 100 nM antithrombin underestimated the maximal affinity loss at saturating antithrombin. Calculation of the maximal affinity decrease from the linkage equation given in Methods
indicated a ~5-fold loss in affinity of EP for thrombin at saturating levels of antithrombin, a value comparable to the loss in affinity observed with aPC and factor Xla at near saturating antithrombin levels. The reciprocal ~5-fold effects of thrombin binding on antithrombin binding and vice versa are consistent with the two interactions being thermodynamically linked. Notably, the linkage is modest, antithrombin binding to EP217609 still resulting in strong direct thrombin inhibition (K_I ~200 pM) and thrombin binding minimally affecting the binding of antithrombin at plasma antithrombin concentrations (reduction from 99% to 93%).

Avidin effectively neutralizes the dual inhibitor moieties of EP217609 - EP217609 contains a biotin tag that allows neutralization of the compound in vivo upon avidin administration through accelerated clearance. To determine whether avidin binding directly affected the compound’s dual inhibitor activities, we compared EP217609 inhibition of thrombin and factor Xa in the absence and presence of a 1-2-fold molar excess of avidin. Avidin markedly weakened the direct inhibitory effect of EP217609 on thrombin, the K_I increasing 100-fold from 43±16 pM to 4.4±0.3 nM (Fig. 6). Avidin had no effect on the K_I for thrombin inhibition by the nonbiotinylated EP42675. The observation that the apparent K_I measured in the presence of avidin was unaffected by doubling the substrate concentration indicated that no correction of this K_I for substrate competition was necessary. This implied that avidin weakened the K_I not by increasing k_off, but instead by decreasing k_on.

Avidin reduced k_obs for EP217609-antithrombin complex inhibition of factor Xa by ~5-fold, but had no effect on EP42675-antithrombin complex inhibition (Fig. 7A). To verify that this was due to a reduced affinity of antithrombin for the EP217609-avidin complex, we performed kinetic titrations of antithrombin with free and avidin-complexed EP217609 under conditions where saturable increases in k_obs for antithrombin inhibition of factor Xa provided the
KD for EP compound binding to antithrombin as well as the maximal rate constant associated with full activation of the serpin (Fig. 7B)\textsuperscript{34}. Avidin substantially weakened the binding of EP217609 to antithrombin without affecting the maximal activation. The KDs obtained in the absence and presence of avidin equimolar with the highest EP compound concentration assuming equivalent endpoints were 44±6 nM and 1040±50 nM, respectively, indicating that avidin produces a 20-30-fold reduction in EP217609 affinity for antithrombin. The observed ~5-fold reduction in the apparent EP-accelerated rate constant but ~20-30-fold reduction in EP affinity for antithrombin is a consequence of the antithrombin concentration used to measure the rate constant exceeding the KD for EP compound binding in the absence of avidin but being well below KD in the presence of avidin. When the apparent rate constants measured are corrected for the increase in KD caused by avidin, equivalent second order rate constants of 7.6±1.2 x 10\textsuperscript{5} M\textsuperscript{-1}s\textsuperscript{-1} and 7.7±0.9 x 10\textsuperscript{5} M\textsuperscript{-1}s\textsuperscript{-1} for the antithrombin-EP217609 complex reaction with factor Xa in the absence and presence of avidin, respectively, were obtained.

**Discussion**

Previous reports have documented the potent anti-IIa and anti-factor Xa activities of EP217609 and its nonbiotinylated counterpart EP42675 in plasma, as well as the favorable pharmacokinetic properties, sustained antithrombotic activity and avidin-mediated neutralization of EP217609 in vivo\textsuperscript{15,17}. In the present study, we have performed a comprehensive biochemical characterization of EP217609 and EP42675 potency and selectivity to provide new mechanistic insights into the potent antithrombotic activity of EP217609. Our results show that the inhibitors possess a high degree of specificity for their targets, (K\textsubscript{I} 30-60 pM for thrombin and k\textsubscript{ass} 6-7 x 10\textsuperscript{5} M\textsuperscript{-1}s\textsuperscript{-1} for factor Xa) as well as a marked selectivity for these proteases (K\textsubscript{I} >1000-fold greater and k\textsubscript{ass} >20-fold slower for all other coagulation and fibrinolytic proteases tested).
The biotin tag was found to minimally perturb the specificity and selectivity toward the dual targets in either of its stereoisomeric configurations, thereby providing a nonperturbing means for neutralizing the compound’s activity with avidin. Notably, avidin binding to EP217609 was found to cause a large loss in inhibitor potency (100-fold increase in $K_I$ for thrombin and 20-30-fold increase in the $K_D$ for antithrombin binding), contributing to an immediate neutralization of the drug’s activity in addition to the indirect neutralization caused by avidin accelerating its clearance$^{15,35}$. Phase I clinical studies in man have indeed shown that administration of avidin triggers a rapid and irreversible neutralization of EP217609 without rebound effect.$^{18}$

The selectivity of EP217609 as a direct thrombin inhibitor largely derives from the extremely high affinity of the $\alpha$-NAPAP-like moiety for thrombin ($K_I$ 30-40 pM) that ranks among the highest affinity direct thrombin inhibitors known$^{6,36}$. This affinity is much greater than that of $\alpha$-NAPAP or related inhibitors such as argatroban$^{37}$, the result of structure-activity optimization that included replacement of the naphthylsulfonamide moiety and incorporation of the active stereoisomer of the amidinophenyl substituent$^{14}$. The kinetics of inhibition are rapid and conform to a simple one-step reversible equilibrium with no evidence for any induced-fit slow binding step. The protease with the next highest affinity, aPC, was inhibited with a $K_I$ value of $\sim 10^{-7}$ M, that was 1000-fold higher than that for thrombin. Factor Xla was inhibited with an even higher $K_I$ approaching micromolar and all other proteases were inhibited with $K_I$ values exceeding $10^{-6}$ M. This selectivity parallels that previously reported for other $\alpha$-NAPAP analogues, although those with considerably reduced specificity for thrombin$^{36}$. The biotin tag somewhat enhanced the affinity for all proteases except aPC, thereby contributing to the high selectivity of EP217609 for thrombin over aPC. Since EP217609 is expected to act pharmacologically with antithrombin bound, it was important to find that antithrombin binding
EP217609 and the nonbiotinylated EP42675 were found to act like the natural heparin pentasaccharide, fondaparinux, or its higher affinity mimetic, idraparinux, in transforming antithrombin into a highly selective factor Xa inhibitor\textsuperscript{25}. Thus, comparison of the relative values of $k_{\text{ass}}$ for reaction of proteases with antithrombin complexed with any of the EP compounds showed that EP compound activation of antithrombin, as with fondaparinux or idraparinux activation, alters the specificity profile of antithrombin to favor inhibition of factor Xa over all other proteases. Factor Xa is thus inhibited by the antithrombin-EP compound complex with a rapid rate constant of $\sim 10^6$ M$^{-1}$s$^{-1}$ whereas all other coagulation and fibrinolytic proteases whose inhibition rate could be measured are inhibited 20-50,000-fold slower than factor Xa.

Importantly, the two inhibitor moieties of EP217609 were found to act in a largely independent manner with relatively modest $\sim 5$-fold linkage effects of the binding of one protein on the binding of the other. Either inhibitor moiety thus retains a high potency irrespective of whether the other moiety is bound to its protein ligand. The flexible spacer unit that separates the two inhibitor moieties thus allows each inhibitor to act independently. By contrast placement of the biotin tag at the junction between the two inhibitor moieties results in a larger effect of avidin binding on the inhibitor interactions with their protein ligands.

The present report together with prior reports shows that the strategy of combining two separate inhibitor moieties with distinct mechanisms of action yields an anticoagulant with unprecedented pharmacological properties. Thus, the predictable pharmacokinetic properties of the fondaparinux analogue are transferred to a direct thrombin inhibitor, making EP217609 a
unique anticoagulant. Its potent antithrombotic activity in both venous and arterial thrombosis models is in part related to its ability, shared with other direct thrombin inhibitors, to inactivate clot bound thrombin as well as free thrombin. Importantly, its long half-life, predictable pharmacokinetics and neutralizability cannot be replicated by co-administration of the individual inhibitor compounds. EP217609 thus shows great promise in overcoming the limitations of current anticoagulants, and the EP217609-avidin couple represents an attractive anticoagulation system for cardiopulmonary bypass. Ongoing clinical trials will tell if this new system offers a better benefit/risk ratio than the heparin-protamine system that has been used for over 60 years in this indication.

**Acknowledgements**- This work was supported in part by a contract with Endotis Pharma and by NIH grant R37 HL-39888 (both to STO). We thank Dr. Peter Gettins of the University of Illinois at Chicago for helpful comments on the manuscript.

**Authorship Contribution and Disclosure of Conflicts of Interest:** STO and MP designed the research study, RS acquired the research data, RS and STO analyzed and interpreted data and STO and MP wrote the manuscript. STO and RS have no conflicts of financial interest to disclose. MP is employed by Endotis Pharma as Head of Preclinical Research and Development.
References

32. Hjelm R, Schedin-Weiss S. High-affinity interaction between a synthetic, highly negatively charged pentasaccharide and α- or β-antithrombin is predominantly due to nonionic interactions. Biochemistry. 2007;46(11):3378-3384.
33. Olson ST, Bock PE, Kvassman J, et al. Role of the catalytic serine in the interactions of serine proteinases with protein inhibitors of the serpin family.


Table 1: *Equilibrium dissociation constants for the binding of EP compounds to antithrombin in I 0.15, pH 7.4 buffer containing 5 mM Ca\(^2+\) at 25°C*

Dissociation constants for antithrombin-EP compound interactions were measured by fitting fluorescence titrations of antithrombin with the compounds by the quadratic equilibrium binding equation as described in Methods. Fondaparinux served as a control. Reported dissociation constants are averages±range from at least two titrations.

<table>
<thead>
<tr>
<th>EP compound</th>
<th>(K_D) (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fondaparinux(^a)</td>
<td>60±10</td>
</tr>
<tr>
<td>EP42675</td>
<td>30±1</td>
</tr>
<tr>
<td>EP217609</td>
<td>32±4</td>
</tr>
<tr>
<td>EP217609-1</td>
<td>34±4</td>
</tr>
<tr>
<td>EP307138-1</td>
<td>39±3</td>
</tr>
</tbody>
</table>

\(^a\) Taken from reference 19.
Table 2: **Dissociation constants (K_i) for EP compound inhibition of blood coagulation proteases in I 0.15, pH 7.4 buffer plus 5 mM Ca^{2+} at 25°C** - Dissociation constants were measured by fitting the hyperbolic decrease in the initial velocity of substrate hydrolysis as a function of EP compound concentration to the equation for binding of a competitive inhibitor as described in Methods and depicted in figure 3. Fits provided apparent dissociation constants, K_i*, which were corrected by dividing by the factor, 1 + [S]_o/KM, to obtain K_i. Correction factors ranged between 1.1-4.3. No correction was required in the case of EP compound binding to thrombin because of the tight binding of the inhibitor and consequent negligible dissociation during measurements of initial velocity.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Thrombin</td>
<td>6.1±2.0 \times 10^{-11}</td>
<td>4.3±1.6 \times 10^{-11}</td>
<td>3.8±0.8 \times 10^{-11}</td>
<td>5.0±0.9 \times 10^{-11}</td>
</tr>
<tr>
<td>FXa</td>
<td>&gt;10^{-3}</td>
<td>&gt;10^{-3}</td>
<td>&gt;10^{-3}</td>
<td>&gt;10^{-3}</td>
</tr>
<tr>
<td>FIXa</td>
<td>&gt;10^{-3}</td>
<td>&gt;10^{-3}</td>
<td>&gt;10^{-3}</td>
<td>&gt;10^{-3}</td>
</tr>
<tr>
<td>TF-FVIIa</td>
<td>&gt;10^{-3}</td>
<td>&gt;10^{-3}</td>
<td>&gt;10^{-3}</td>
<td>&gt;10^{-3}</td>
</tr>
<tr>
<td>FXIa</td>
<td>2.9±0.2 \times 10^{-7}</td>
<td>1.7±0.1 \times 10^{-7}</td>
<td>3.2±0.2 \times 10^{-7}</td>
<td>8.6±0.5 \times 10^{-8}</td>
</tr>
<tr>
<td>FXIIa</td>
<td>&gt;10^{-3}</td>
<td>&gt;10^{-3}</td>
<td>&gt;10^{-3}</td>
<td>&gt;10^{-3}</td>
</tr>
<tr>
<td>Kallikrein</td>
<td>2.2±0.1 \times 10^{-5}</td>
<td>1.3±0.1 \times 10^{-5}</td>
<td>1.5±0.1 \times 10^{-5}</td>
<td>1.1±0.1 \times 10^{-5}</td>
</tr>
<tr>
<td>aPC</td>
<td>4.0±0.3 \times 10^{-8}</td>
<td>5.0±0.6 \times 10^{-8}</td>
<td>5.2±0.4 \times 10^{-8}</td>
<td>6.3±0.4 \times 10^{-8}</td>
</tr>
<tr>
<td>tPA</td>
<td>2±1 \times 10^{-4}</td>
<td>&gt;10^{-3}</td>
<td>&gt;10^{-3}</td>
<td>&gt;10^{-3}</td>
</tr>
<tr>
<td>Plasmin</td>
<td>5.2±0.3 \times 10^{-6}</td>
<td>2.7±0.2 \times 10^{-6}</td>
<td>1.8±0.2 \times 10^{-6}</td>
<td>2.6±0.2 \times 10^{-6}</td>
</tr>
</tbody>
</table>
Table 3: Association rate constants (k_{ass}) for the inhibition of procoagulant and anticoagulant blood coagulation proteases by antithrombin complexes with idraparinux and EP compounds in 10.15, pH 7.4 buffer plus 5 mM Ca^{2+} at 25°C. Second order rate constants for reactions of antithrombin-EP compound complexes with proteases were determined under pseudo-first order conditions based on exponential fits of reaction progress curves obtained at different concentrations of antithrombin complexes as described in Methods. Reported rate constants are average values from at least two progress curves with errors representing the range of values.

<table>
<thead>
<tr>
<th>Protease</th>
<th>[AT-EP complex]</th>
<th>k_{ass} (M^{-1}s^{-1})</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thrombin</td>
<td>1.46±0.01 x 10^4</td>
<td>--</td>
</tr>
<tr>
<td>FXa 0.001-0.02 μM</td>
<td>6.73±0.16 x 10^5</td>
<td>6.57±0.07 x 10^5</td>
</tr>
<tr>
<td>FIXa 0.1-0.5 μM</td>
<td>3.87±0.28 x 10^4</td>
<td>3.35±0.13 x 10^4</td>
</tr>
<tr>
<td>TF-FVIIa 0.5-1 μM</td>
<td>6.48±0.19 x 10^3</td>
<td>4.84±0.05 x 10^3</td>
</tr>
<tr>
<td>FXIa 1-2 μM</td>
<td>9.92±0.08 x 10^2</td>
<td>5.95±0.07 x 10^2</td>
</tr>
<tr>
<td>FXIIa 1-2 μM</td>
<td>2.10±0.09 x 10^3</td>
<td>2.80±0.01 x 10^3</td>
</tr>
<tr>
<td>Kallikrein 0.6-2 μM</td>
<td>2.08±0.07 x 10^3</td>
<td>1.69±0.11 x 10^3</td>
</tr>
<tr>
<td>aPC 20-30 μM</td>
<td>2.09±0.24</td>
<td>--</td>
</tr>
<tr>
<td>tPA 20-60 μM</td>
<td>1.36±0.02 x 10^1</td>
<td>1.27±0.15 x 10^1</td>
</tr>
<tr>
<td>Plasmin 0.3-0.6 μM</td>
<td>1.52±0.04 x 10^4</td>
<td>1.09±0.08 x 10^4</td>
</tr>
</tbody>
</table>
Figure Legends

Figure 1: **Structure of EP217609** The indirect factor Xa inhibitor moiety (fondaparinux analogue), direct thrombin inhibitor moiety and biotin label of EP217609 are indicated. The biotin is attached to the linker between the two inhibitor moieties through a lysine spacer indicated by the arrow. EP217609 is a mixture of diastereomers containing either an L-lysine spacer (EP217609-1) or a D-lysine spacer (EP307138-1). EP42675 lacks the lysyl-biotinyl group indicated by a box.

Figure 2: **Equilibrium binding of antithrombin and thrombin to EP compounds** A, Relative protein fluorescence changes (F<sub>obs</sub>/F<sub>o</sub>) accompanying the stepwise addition of EP42675 (open symbols) or EP217609 (closed symbols) to 500 nM antithrombin in 0.05 sodium phosphate buffer (O, ●) or to 200 nM antithrombin in 0.15 Hepes plus Ca<sup>2+</sup> buffer (▲, ▲) both at pH 7.4, 25°C, are plotted as a function of the molar ratio of EP compound to antithrombin. Solid lines are fits to the quadratic equilibrium binding equation from which the binding stoichiometry, the K<sub>D</sub> (fixed at 0.5 nM for 0.05 titrations) and the maximal fluorescence change were derived. B, Relative changes in p-aminobenzamidine fluorescence (F<sub>obs</sub>/F<sub>o</sub>) accompanying the stepwise addition of EP42675 (O) or EP217609 (●) to 200 nM thrombin plus 100 μM p-aminobenzamidine are plotted as a function of the molar ratio of EP compound to thrombin. Titrations were fit by the quadratic equilibrium binding equation in which K<sub>D</sub> was fixed at a value of 0.1 nM based on measurements of K<sub>I</sub> and the competitive effect of probe binding to obtain values for the binding stoichiometry and maximal fluorescence change.

Figure 3: **Specificity and selectivity of EP compounds as direct inhibitors of blood coagulation proteases** The relative decrease of the initial velocity of hydrolysis of specific reporter substrates by the indicated proteases is shown as a function of EP compound concentration. Data for the six proteases that were significantly inhibited up to 10<sup>-4</sup> M EP compound are shown as a function of increasing EP42675 (open symbols) or EP217609 (solid symbols) concentration. Data for EP217609 only is presented for the four proteases whose activity was insignificantly inhibited over the same EP compound concentration range. Solid and dashed lines are fits of EP217609 and EP42675 data, respectively, by equations for tight binding or regular competitive inhibition which yielded values of K<sub>I</sub>*. K<sub>I</sub> was calculated from K<sub>I</sub>* by dividing the latter by the factor for competitive substrate inhibition except for the K<sub>I</sub>* measured for thrombin which required no correction. K<sub>I</sub> values are tabulated in Table 2.

Figure 4: **Equilibrium and kinetics of EP compound binding to thrombin** A, Comparison of equilibrium binding titrations of 0.12 and 1.2 nM thrombin with EP217609 monitored from the decrease in the initial rate of S2366 substrate hydrolysis by thrombin as in figure 3. Solid lines are fits by the equation for tight binding competitive inhibition. B, Plot of k<sub>obs</sub> vs. the effective [EP compound], obtained by dividing by the factor, 1 + [S]/K<sub>M</sub>, for the binding of EP42675 (O) and EP217609 (●) to thrombin. k<sub>obs</sub> was measured from exponential progress curves of the time-dependent inhibition of thrombin hydrolysis of the low K<sub>M</sub> substrate, Tosyl-GPR-AMC. The slope of this plot provided k<sub>on</sub> and the intercept provided k<sub>off</sub>.

Figure 5: **Linkage effects on inhibitor potency of EP compounds** A, Shown are the decrease in initial velocities of substrate hydrolysis for thrombin, aPC and factor Xla measured as a function of increasing EP217609 concentration in the absence (solid symbols) or presence (open symbols) of 0.1, 0.5 and 1 μM antithrombin, respectively. Solid and dashed lines are fits to the competitive binding equations in the text for titrations in the absence or presence of
antithrombin, respectively. Values of $K_I^*$ obtained from fits were corrected for competitive substrate binding for aPC and factor Xla. B, Progressive inhibition of factor Xa by increasing concentrations of antithrombin-EP42675 (triangles) and -EP217609 (circles) complexes was measured in the absence (open symbols) and presence (closed symbols) of thrombin levels equimolar with EP compound for reactions containing 200 nM antithrombin, 0.5 nM factor Xa and the indicated EP concentrations for a fixed reaction time of 300 s. Inverted triangles are controls in which antithrombin was omitted from factor Xa reactions with equimolar EP42675 and thrombin. Solid lines are fits by a single exponential decay function which yielded $k_{obs}$ values. These were used to calculate the dissociation constant for antithrombin binding to the EP-thrombin binary complex as described in Methods.

Figure 6: **Effect of avidin binding on EP217609 direct inhibition of thrombin**- Titrations of the decrease in substrate hydrolysis activity (100 μM S2366) of ~1 nM thrombin as a function of added EP42675 (circles) or EP217609 (triangles) in the absence (closed) or presence (open) of 50 nM avidin. The effects of doubling the avidin or S2366 concentration in EP217609 titrations is shown by the open and closed inverted triangles, respectively. Titrations were fit by the equation for tight binding to obtain $K_I$ values.

Figure 7: **Effect of avidin on EP217609-accelerated antithrombin inhibition of factor Xa**- A, EP217609-accelerated antithrombin inhibition of factor Xa activity is shown as a function of EP217609 concentration in the absence and presence of avidin. Reactions contained 200 nM antithrombin, 5 nM factor Xa, the indicated EP compound concentration and 0 (●), 12 nM (▲) or 24 nM (△) avidin as indicated for a fixed reaction time of 300 s. Solid lines are fits by a single exponential function from which $k_{obs}$ was obtained. B, Kinetic titrations of the binding of EP217609 to 50 nM antithrombin in the absence (●) and presence (▲) of 1000 nM avidin followed from the enhancement by the EP compound of the rate of antithrombin inhibition of 5 nM factor Xa. Plotted are observed pseudo-first order rate constants ($k_{obs}$) calculated from the extent of antithrombin inhibition of factor Xa in the presence of the indicated concentrations of EP217609 in the absence or presence of avidin for 1 minute reactions. Solid lines are fits to the quadratic binding equation from which $K_D$ for the antithrombin-EP217609 interaction and the maximal rate constant for the antithrombin-EP217609 reaction with factor Xa were obtained. It should be noted that reciprocal effects of antithrombin binding on avidin binding are insignificant because avidin binds biotin with a femtomolar $K_D$. 

From www.bloodjournal.org by guest on November 16, 2017. For personal use only.
Figure 1

Fondaparinux analogue

Biotin

Direct Thrombin Inhibitor
Figure 2

(A) Graph showing the relationship between $F_{\text{obs}} / F_0$ and $[\text{EP compound}] / [\text{AT}]_0$.

(B) Graph showing the relationship between $F_{\text{obs}} / F_0$ and $[\text{EP compound}] / [\text{Thrombin}]_0$. 

For personal use only.
Figure 4

A

\[ 100 \times \frac{v_{obs}}{v_0} \]

\[ [\text{EP217609}] \text{ (nM)} \]

- 0.12 nM \( \text{IIa} \) \( K_i = 28 \pm 5 \text{ pM} \)
- 1.2 nM \( \text{IIa} \) \( K_i = 39 \pm 9 \text{ pM} \)

B

\[ k_{obs} \text{ (s}^{-1}) \]

\[ [\text{EP compound}]_o / (1+[S]_o / K_M) \text{ (nM)} \]

- EP42675
- EP217609
Figure 5

A

B

% residual FXa activity

[EP compound]₀ (nM)

[EP217609]₀ (M)
Figure 6

% residual thrombin activity vs. [EP compound]₀ (nM)
Specificity and selectivity profile of EP217609: a new, neutralizable, dual-action anticoagulant that targets thrombin and factor Xa

Steven T. Olson, Richard Swanson and Maurice Petitou